Objective We compared the long-term clinical and 1-year angiographic outcomes in ST-segment elevation myocardial infarction (STEMI) patients who presented between 12 to 48 hours after symptom onset and underwent emergent procedures (late reperfusion) using sirolimus-eluting stents (SES; Cypher Bx Velocity) with those of primary stenting patients who presented within 12 hours. Methods The study design was a retrospective, nonrandomized single-center study in which the investigations were conducted in October 2012 following the enrollment of consecutive STEMI patients treated with late reperfusion (n=75) and primary stenting using SES (n=386) between September 2004 and May 2007. The incidence of the primary end points (cardiac death, nonfatal recurrent MI and definite stent thrombosis) after late reperfusion (6.7%; mean follow-up, 2,176±742 days) was not significantly different from that observed after primary stenting (8.5%; 2,237±722 days) (p=0.59). The incidence of the secondary end point (binary in-stent restenosis: % diameter stenosis greater than 50% on secondary angiography at approximately one year) after late reperfusion (11.1%, n=54) was not statistically different from that observed after primary stenting (8.0%, n=276) (p=0.45). Using a propensity score matching analysis, the incidences of the primary (6.7%, n=75) and secondary (11.3%, n=53) end points after late reperfusion were not found to be significantly different from those observed after primary stenting (8.0% and 9.4%) (p=0.75 and 0.75, respectively). Conclusion The present small study showed the long-term clinical and 1-year angiographic outcomes after late reperfusion using SES for STEMI patients in emergent procedures in daily practice to be statistically equivalent to those observed after primary stenting using SES for STEMI patients.
Introduction
The short-and mid-term safety and efficacy of primary stenting (treatment within 12 hours from the onset of symptoms) using sirolimus-eluting stents (SES; Cypher Bx Velocity) compared to bare-metal stents (BMS) in ST-segment elevated myocardial infarction (STEMI) patients have been consistently reported in Japan (1) (2) (3) (4) (5) . However, the Japanese Circulation Society (JCS) guidelines for the management of STEMI patients state that there is little evidence for the long-term safety of drug-eluting stent (DES) use for primary stenting in STEMI patients (6) . Therefore, it is necessary to examine the long-term safety of SES for the treatment of STEMI patients in Japan, where the incidence of severe cardiac events, such as stent thrombosis, is less frequent than that observed in Western countries (2, 3, 7, 8) .
In addition to the concept of the safety and efficacy of primary stenting using DES in STEMI patients in Japan (1) (2) (3) (4) (5) , the use of invasive treatment during emergent procedures (late reperfusion) in STEMI patients presenting more than 12 hours after symptom onset has also widely spread in daily practice. However, while the safety, efficacy and benefits of late reperfusion have been reported (3, 9, 10) , the JCS (6) and American College of Cardiology/American Heart Association (ACC/AHA) (11) guidelines do not recommend invasive therapy for STEMI patients presenting after 12 hours with stable hemodynamics. This is due to the lack of reports showing long-term clinical outcomes of late reperfusion in STEMI patients using both DES and BMS. Therefore, the outcomes of late reperfusion using DES and various progressive modalities for reperfusion in STEMI patients must be evaluated in the present advanced percutaneous coronary intervention (PCI) era.
In the present study, we intended to evaluate the longterm outcomes of late reperfusion using SES in STEMI patients in recent daily practice in a DES-available environment. For this purpose, we compared the long-term clinical and angiographic outcomes after late reperfusion using SES in STEMI patients during emergent procedures with those of primary stenting patients by enrolling consecutive STEMI patients from a cohort of almost unrestricted use of SES evaluated in our previous report (2) . The clinical outcomes of primary stenting using SES were evaluated by extending the clinical observational interval compared to that used in our previous reports (1) (2) (3) and comparing the outcomes with those of prospective randomized studies from Western countries (12, 13) .
Materials and Methods

Study design
The present study was a retrospective, nonrandomized single-center study conducted at Saitama Cardiovascular Respiratory Center. The retrospective examination was performed in October 2012. (A) The selection of the stents (SES or BMS, SES approval obtained in August 2004), (B) reperfusion methods used to achieve thrombolysis in the myocardial infarction (TIMI)-3 grade flow, such as distal protection methods and thrombosuction using thrombectomy catheters to prevent the development of slow-or no-reflow phenomena (Tables 1, 3 ), (C) thienopyridine agent administration duration, (D) assignment to perform the follow-up angiogram (fu CAG) and (E) the drugs administered for secondary prevention (14) were not randomized. All patients were informed about the reperfusion therapy, and consent was obtained from the patients and/or their families in the emergency room.
Population
From September 2004 to May 2007 (at the time, TAXUS Express was approved as the second DES in Japan), 526 first Japanese STEMI patients without prior coronary artery bypass grafts (CABGs) were treated at our institute. Among them, 47 STEMI patients (35 patients presenting within 12 hours and 12 patients presenting between 12 to 48 hours after symptom onset) were not treated using coronary stents (i.e., SES or BMS) during emergent procedures. The reasons for not being treated with either SES or BMS in the patients presenting within 12 hours and beyond 12 hours were as follows: indication for CABG (n=9 and 7); no critical stenosis or thrombi with a TIMI grade 3 flow (a TIMI grade 3 flow on the first angiogram), including patients with vasospastic angina (n=7 and 1); complications with cardiac rupture (n=5 and 0); a small reference diameter and/or a small arterial territory (n=5 and 0); aging without consent (n=3 and 1); complication with congestive heart failure and chronic renal failure without chest symptoms (n=2 and 1); inability to define the infarct-related artery (n=1 and 1); a terminal state of malignancy (n=1 and 1); unconsciousness (n=2 and 0); and embolic occlusion due to atrial fibrillation (n=0 and 1). Hence, 479 STEMI patients were treated for native coronary culprit lesions with either SES (n=461) or BMS (n=18) during emergent procedures. Therefore, the percentage of SES (DES) use among the patients treated with coronary stents during emergent procedures was 96.2%. The reasons for BMS use were as follows: known malignancy, a preoperative status, a large reference vessel diameter, impossibility of speaking with the patient due to cardiogenic shock, a very short lesion length and impossibility of delivering SES, as described in our previous report (2) . Among the patients treated with BMS, only one patient presented between 12 and 48 hours. Among the 461 patients treated with SES, 386 presented within 12 hours (termed the primary stenting group) and 75 presented between 12 and 48 hours after symptom onset (termed the late reperfusion group). Therefore, the percentage of patients with primary stenting using SES was 83.7%.
After reperfusion, all patients were encouraged to undergo optimal medical therapy according to the guidelines for the management and secondary prevention of MI, as outlined by the JCS (14) . Oral beta-blockers (β-blockers), angiotensinconverting enzyme inhibitors (ACE-Is) or angiotensin receptor-blockers (ARB) (ACE-Is/ARBs) and lipid-lowering therapy using HMG-CoA reducing agents (statins) were continuously administered after discharge (Table 1) .
Reperfusion procedures and antiplatelet therapy
The choice of the device used to restore a good coronary flow was subject to the doctor's discretion, as described above. The stents were implanted via visual angiographic estimation to cover the entire baseline lesion, and following SES approval, were implanted largely under the guidance of intravascular ultrasonography (IVUS-guide) ( further stent dilation was needed, high-pressure ballooning using a noncompliant balloon was typically carried out (Tables 1, 3). Periprocedural antiplatelet therapy was administered as previously reported (1-3, 9, 15-17) . In the emergency care unit, before performing primary PCI, aspirin (162-200 mg) and ticlopidine (200 mg) were immediately administered orally. After the procedure, ticlopidine (200 mg/day) was prescribed for at least 12 weeks in the SES group. If ticlopidine resulted in adverse effects, cilostazol (200-300 mg/day) or clopidogrel (75 mg/day) were administered at the doctor's discretion.
End points
The primary end point as the safety end point of the clinical outcomes was the cardiac event composite of death without definite noncardiac death (in-hospital mortality and postdischarge mortality), nonfatal recurrent myocardial infarction and definite stent thrombosis (ST), as defined by the Academic Research Consortium (ARC) (18) . Additional outcomes of interest were possible ST defined by the ARC (18) and all-cause death. The secondary end point as the efficacy end point of the angiographic outcomes was the incidence of binary in-stent restenosis (defined below). Target lesion revascularization (TLR) observed on the fu CAG was defined as elective, emergency repeated PCI or CABG, performed for definite ST and in-stent restenosis, including at both the 5-mm proximal and distal stent margins. The need for TLR was determined based on visual angiographic outcomes, as in our former reports (2, 3, 16, 17) . 
Quantitative coronary artery angiography (QCA)
The fu CAG was planned at approximately one year. The number of patients discharged alive was 72 in the late reperfusion group and 370 in the primary stenting group (Table 1). Therefore, the percentages of patients receiving follow-up for the fu CAG in the late reperfusion and primary stenting groups were 75.0% (54 of 72) and 74.6% (276 of 370, no significant difference), respectively.
The QCA parameters were measured using the TCS cardiovascular network systems (CAAS-2 and -5 systems, Netherlands), as previously described (2, 3, (15) (16) (17) . Values were obtained at three points: before PCI (preprocedural), immediately after successful PCI (postprocedural) and at the chronic phase (follow-up). The minimal lumen diameter (MLD), % diameter stenosis (%DS), reference diameter (RD) and lesion length were measured. In addition, acute gain (postprocedural MLD minus preprocedural MLD) and late luminal loss (postprocedural MLD minus follow-up MLD) were calculated. Binary in-stent restenosis (binary restenosis) was defined as a %DS of >50% at fu CAG. In occluded lesions, %DS was defined as 100 and the MLD was defined as 0.
Estimated variables
The definitions of the variables used as baseline characteristics, in particular, patient, angiographic, procedural characteristics, QCA and medications at discharge, were as follows: age at primary stenting; male gender; diabetes mellitus status; cardiac dysfunction (a left ventricle ejection fraction of less than 40 as evaluated on ultrasonography, left ventriculography or scintigraphy); Killip classification 3-4 (Killip classification 3 or 4); TIMI grade 2-3 flow (a TIMI grade 2 or 3 flow on the first angiogram); Rentrop grade 0-1 (Rentrop grade 0 or 1 for the collateral flow); culprit lesion location in the left anterior descending (LAD) artery; severe calcification (estimated using an angiogram and IVUS); LAD ostium (ostium lesion of LAD), massive thrombus (the previous 3 variables were defined according to the ACC/AHA classification of lesions) (19) ; number of stents (number of implanted stents per lesion); stent diameter (the maximum diameter of the balloon used to dilate the stent); stent length (calculated by adding the length of each stent, regardless of overlap); maximum pressure at the maximum inflation diameter of the balloon; IVUS guide (IVUS availability during PCI); thrombectomy using any thrombosuction catheters; distal protection (lesions treated with the PercuSurge GuardWire device); the final TIMI grade 2-3 flow (a postprocedural TIMI grade 2 or 3 flow); results of blood samples obtained on presentation: the serum lactate dehydrogenase (serum LDH at presentation) level, serum, the serum creatinine (serum Cr at presentation) level, the peak serum level of myocardial creatine kinase isoenzyme (serum peak CK-MB) measured every three hours in the primary stenting using SES group; and the clinical observational duration (observational duration from presentation until being censored).
Statistical analyses
Baseline characteristic variables are expressed as the mean ± standard deviation (SD). Variables and end points in the late reperfusion group were compared with those in the primary stenting group using unpaired t-tests for continuous values and χ 2 or Fisher's tests for categorical values. A propensity score matching analysis was performed to adjust the baseline values among the two groups. The approximate number of variables to adjust was decided by dividing the number of patients in the smaller group (i.e., the late reperfusion group) by 8. Therefore, in order to evaluate the primary and secondary end points, nine and seven variables were selected in each analysis. Taking into consideration, the consistent predictors of cardiac events, nine variables (age, diabetes, cardiac dysfunction, Killip classification 3-4, LAD ostium (20) , severe calcification, stent diameter, postprocedural RD and the serum Cr level at presentation (21)) were adjusted with the caliper value of 0.02. Similarly, in order to evaluate the secondary end point, seven variables (diabetes, LAD, severe calcification, stent length, postprocedural MLD, postprocedural %DS and postprocedural RD) were adjusted with the caliper value of 0.02. A p-value of less than 0.05 was considered to be statistically significant.
The Stata for Windows version 12 software program (StataCorp, College Station, TX, USA) was used for the statistical analyses. Table 1 shows the baseline characteristics of the patients in the primary stenting group (n=386) and the late reperfusion group (n=75). Among the nine variables in the patient characteristics, the serum LDH level on ER admission was significantly different between the groups (p<0.001). Among the seven variables in the angiographic characteristics, the percentage of LAD ostium was significantly different between the groups (p=0.039). Among the seven variables in the procedural characteristics, the percentages of thrombectomy and distal protection and the mean stent diameter were significantly different between the groups (p=0.005, 0.011, and 0.043, respectively). Among the six variables in the QCA, the mean value of postprocedural RD was significantly different between the groups (p=0.025). The incidences of the primary end point, primary end point-related variables and all-cause death in the late reperfusion group were not significantly different from those observed in the primary stenting group. Table 2 shows the adjusted baseline characteristics of the patients in the primary stenting group and the late reperfusion group (n=75 in each arm). The incidence of the primary end point was not significantly different between the groups. Table 3 shows the baseline characteristics of the patients who underwent fu CAG in the primary stenting group (n= 276) and the late reperfusion group (n=54). Among the nine variables in the patient characteristics, the serum LDH level at presentation was significantly different between the groups (p<0.001). Among the seven variables in the angiographic characteristics, the percentages of LAD and Rentrop grade 0-1 were significantly different between the groups (p=0.025 and 0.037, respectively). Among the seven variables in the procedural characteristics, the percentages of thrombectomy and distal protection were significantly different between the groups (p=0.001 and 0.003, respectively). Among the nine variables in the QCA, the mean value of postprocedural RD was significantly different between the groups (p=0.047). The incidence of the secondary end point in the late reperfusion group was not significantly different from that observed in the primary stenting group. Table 4 shows the adjusted baseline characteristics of the patients in the primary stenting group and the late reperfusion group (n=53 in each arm). The incidence of the secondary end point was not significantly different between the groups.
Results
Baseline characteristics and incidences of the primary end point
Adjusted baseline characteristics and incidence of the primary end point
Baseline characteristics and incidences of the secondary end point in the patients who underwent fu CAG
Adjusted baseline characteristics and incidence of the secondary end point
Discussion
The major findings of the present study are that the longterm (approximately 6-year interval) clinical outcomes and angiographic outcomes (at an approximately 1-year interval) after late reperfusion using SES in STEMI patients during emergent procedures in a daily practice environment were statistically equivalent to those obtained after primary stenting using SES in STEMI patients (Tables 1-4 ). To our knowledge, this is the first study showing the statistical equivalency of clinical and angiographic outcomes between primary stenting and late reperfusion using both SES and BMS in STEMI patients with the longest clinical observational interval (1-5, 12, 13) .
The benefits of late reperfusion in STEMI patients include relief from persistent myocardial ischemia, myocardial salvage, electrophysiological stabilization and decreased cost due to shortened hospitalization (9, 10). However, both the JCS and ACC/AHA guidelines do not recommend invasive therapy for stable STEMI patients presenting more than 12 hours from symptom onset (6, 11) . The lack of reports showing long-term clinical outcomes of late reperfusion in STEMI patients using both DES and BMS, including invasive therapy, plays a role in these guidelines. The present paper sought to evaluate the safety and efficacy of widelyspread late reperfusion in STEMI patients using emergent procedures based on recent advances in operator skill and PCI modalities in Japan, where the incidence of severe cardiac events, such as stent thrombosis, is less frequent than that observed in Western countries (2, 3, 7, 8) . The present study reflects the clinical setting and included high-risk patients with complex lesions consistently related to cardiac events and binary restenosis, such as those with cardiac dysfunction, Killip 3-4 classifications, severe calcification, LAD ostium and thrombus-containing lesions. This study also included higher mean peak values of CK-MB >300 (IU/dL) in the primary stenting group and longer stents compared to those used in previous prospective randomized studies (Table 1) (12, 13) . In addition, a lack of use of glycoprotein IIb/IIIa inhibitors and the proportion of diabetic patients (as high as 40%) were other characteristics of the cohort, reflecting daily practice in Japan. The culprit characteristics of the STEMI patients presenting more than 12 hours after onset included the location of the vessel (other than the LAD) and a smaller reference vessel diameter (Table 1) . In addition, according to the tissue characteristics of the culprit location (22) , SES were placed with significantly lower rates of thrombectomy and use of distal protection devices in the late reperfusion group (Table 1) . However, following adjustment of the nine cardiac event-related variables, the present study demonstrated the statistical equivalency of the longterm clinical outcomes between the primary stenting group and the late reperfusion group (Table 2) . From this result, in order to estimate the long-term clinical outcomes of late reperfusion using SES, the clinical outcomes of the present STEMI cohort undergoing primary stenting using SES were assigned as the control outcomes for late reperfusion using SES. The cardiac mortality rate following primary stenting (6.9% in 386 STEMI patients over approximately six years) ( Table 1 ) was similar to the findings of previous randomized studies despite the many disadvantageous baseline values (Table 1 ) (6.9% in 155 STEMI patients during five years in the SEAMI trial (12) and 7.6% in 355 STEMI patients during four years in the TYPHOON study (13)). Therefore, the clinical outcomes of the present STEMI cohort undergoing primary stenting using SES were considered to be acceptable. The incidence of cardiac event in the late reperfusion group (6.7%) was reduced by approximately 40% compared to that reported in the invasive group in the BRAVE-2 study (9) , despite the presence of high-risk patients in the daily practice environment among the present primary stenting group. Therefore, with reference to the long-term safety of primary stenting using SES as discussed above, late reperfusion using SES during emergent procedures, including invasive therapy, exhibited comparable long-term safety in the present cohort. Although the duration of dual antiplatelet therapy was dependent on the doctor's judgment, as described in the Materials and Methods section, the incidence of definite very late stent thrombosis following SES use (1.1% among 461 STEMI patients over approximately six years) ( Table 1) was not high compared to that observed in the Japanese large-scale all comer registry (1.6% among 12,823 patients up to five years) (7) . Therefore, the present study demonstrated the long-term safety of reperfusion using DES (SES) during emergent procedures in STEMI patients presenting within 48 hours among 461 Japanese STEMI patients, confirming the findings of our previous report conducted in a different period among 357 STEMI patients who received either paclitaxel-eluting stents (PES) or SES within 48 hours (3). We also observed statistically equivalent angiographic outcomes following late reperfusion using SES in STEMI patients to those observed after primary stenting (Tables 3, 4 ). The present study showed statistical equivalency between the primary stenting and late reperfusion groups by adjusting seven binary in-stent restenosis-related variables (Table 4). Therefore, the present study demonstrated the statistically equivalent safety and efficacy of late reperfusion using SES in Japanese STEMI patients, including the use of an invasive strategy based on emergent procedures in a daily practice environment, to those of primary stenting with the longest clinical observational intervals currently evaluated (1-5, 12, 13) . Further large-scale, long-term, randomized controlled trials are needed to clarify the durability of both primary stenting and late reperfusion using DES in Japanese STEMI patients.
In the present retrospective, nonrandomized, small singlecenter analysis, the following limitations must be taken into account: First, the selection of stents, such as BMS or SES, from August 2004 to May 2007 (the time for paclitaxeleluting stent approval, TAXUS Express, Boston Sci., USA) and the selection of treatment with PCI or CABG were not randomized. Therefore, in this almost unrestricted SES use cohort, the outcomes of the late reperfusion and primary stenting using SES groups could not be statistically compared with those of the very small number of STEMI patients treated with conservative therapy without emergent procedures, those treated using BMS and those treated without coronary stents, including CABG, as described in the Materials and Methods section. Second, although the number of STEMI patients treated with primary stenting using SES assigned to the control group for late reperfusion using SES was larger than previously reported numbers in the well-known randomized studies described above (12, 13) , the enrolled populations for late reperfusion were small. However, because more than 80% of the STEMI patients presented within 12 hours from symptom onset (Table 1) , it was difficult to examine, on a large scale, patients with STEMI presenting 12 to 48 hours from symptom onset. Third, the baseline values in the STEMI patients, such as the TIMI risk (23) and Syntax scores (24), were not estimated. Fourth, since the mean observational interval was approximately six years, the medicines used for secondary prevention of STEMI were important (14) . The prescribed rates of β-blockers, ACE-Is/ARBs and statins at discharge were not very high (Table 1) . However, the prescribed rates of these drugs in the present study were higher than those in a Japanese standard clinical study from the j-Cypher Registry performed during the same period (25) . Finally, the rate of fu CAG was not extremely high. However, the follow-up QCA data, including the mean late luminal loss, were similar between the two groups (Table 3) .
Conclusion
The present small-scale, single-center study showed that the long-term (mean interval, approximately six years) clinical and 1-year angiographic outcomes of late reperfusion using SES in Japanese STEMI patients, including an invasive strategy, during emergent procedures in a daily practice environment are statistically equivalent to those of primary stenting using SES.
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